Professor of Psychiatry, Charité, Humboldt Universität, Berlin

Birth date: 4th of February 1960

Work address:

Department of Psychiatry of the Charité
Charité – Universitätsmedizin Berlin
Charité Campus Mitte
Charitéplatz1
10117 Berlin
Germany

PROFESSIONAL OBJECTIVE:

Research on neurobiological and sociocultural factors determining mental health

PROFESSIONAL POSITIONS, EDUCATION AND TRAINING:

• Professor of Psychiatry, Director and Chair Department of Psychiatry and Psychotherapy Charité University Medical Center, Campus Mitte Humboldt Universität Berlin (since 2002)
• Professor of Addiction Research, Universität Heidelberg Associate Director, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health Mannheim, Universität Heidelberg (2000-2002)
• Venia legendi (Habilitation) in Psychiatry, Department of Psychiatry of the Freie Universität Berlin (1998)
• Special volunteer, Clinical Brain Disorders Branch, National Institutes of Mental Health, NIH, Bethesda, MD Supported by a scholarship for professorship of the German Research Foundation (DFG) (1995-1997)
• Specialization in Psychiatry, registered by the Chamber of Physicians of Berlin (1994)
• Specialization in Neurology, registered by the Chamber of Physicians of Berlin (1993)
• Specialization in Psychotherapy, registered by the Chamber of Physicians of Berlin (1995)
• Specialization in Social Medicine, registered by the Chamber of Physicians Baden-Württemberg (2000)
• Specialization in Addiction Medicine, registered by the Chamber of Physicians Baden-Württemberg (2002)
• Dissertation (M.D.) “Regression in schizophrenics – historical changes in the application of a pathogenic category.” Magna cum laude. Ruhr-University Bochum (1988).
• MA in Philosophy “The concept of mental health” Cum laude. Freie University Berlin (1994)
• State examination and approbation in medicine (1988)
• Medical studies at the Ruhr-University, Bochum (1980 – 1984).
• Medical studies at the Freie University Berlin (1984 – 1987)
• Philosophical and anthropological studies at the Freie University Berlin and at Howard University, Washington DC (1988 – 1997)
• School education Friedrich-Schiller-Gymnasium Ludwigsburg, Abitur (1967 – 1980).

ADDITIONAL EDUCATION:

• Member of the German Society for Clinical Neurophysiology (examined and admitted, 9/1994).· Electroencephalography and evoked potentials in neurology (12/1988 – 12/1991) & in psychiatry (4/1994 – 10/1994).
• Psychotherapy education in hypnosis, lecturer certificate of the German Society of Hypnosis (DGH) – (6/1993).
• Psychotherapy education acc. to Rogers, certificate by the Society for Scientific Psychotherapy (GWG) – (12/1987).

RESEARCH AWARDS:

Wilhelm-Feuerlein-Award 2000
Serotonergic dysfunction in the disposition and maintenance of alcoholism

TEACHING EXPERIENCES:

• In charge of the regular Course of Psychiatry for Medical Students at the Department of ··Psychiatry of the Humboldt University Berlin (since 2002).
• Teaching Transcultural Psychiatry at the Dept. of· Anthropology (Ethnology) of the Freie Universität Berlin and the Universität Heidelberg (since 2000)
• Teaching the regular Course of Psychiatry for Medical Students at the Department of Psychiatry of the Freie Universität Berlin (1992-1995 & 1999-2001).
• Teaching the regular Course of Neurology for Medical Students at the Neurological University Clinic of the Ruhr-Universität Bochum (1989-1991).
• Teaching nurses in psychiatry and neurology at the University Clinic Rudolf Virchow of the Freie Universität Berlin (1994-1995).
• Teaching physiotherapists in neurology at the Bochum Physiotherapists School of the St. Josef’s Hospital (1989-1991).

CLINICAL AND RESEARCH EXPERIENCE:

• Director and Chair, Department of Psychiatry and Psychotherapy of the Charité, Humboldt Universität Berlin (since 2002)
• Director and Chair, Central Institute of Mental Health, Mannheim University of Heidelberg (declined 2006 due to stay in Berlin)
• Associate Professor of Psychiatry, PET Center, Dept. of Psychiatry, Yale University, New Haven (declined 2001 due to start of work at the Charité)
• Associate Director, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health Mannheim (1999-2002)
• Guest professor, Dept. of Psychiatry, Columbia University, NY (offered 1999, not taken due to start of work in Mannheim)
• Senior clinical supervisor, Department of Neurology, Ruhr-University Bochum (1997-1999)
• Special Volunteer at the Clinical Brain Disorders Branch, NIMH, Washington DC, financed by a scholarship of the DFG (German Research Foundation (1995-1997)
• Scientific assistant at the Department of Psychiatry of the Freie University Berlin (1992-1995)
• Scientific assistant at the Neurological Clinic of the Ruhr-University, Bochum (1988-1991)

JOURNAL BOARDS:

• Member of the Advisory Board of “Pharmacopsychiatry” since 2010
• Member of the Advisory Board of “Deutsches Ärzteblatt” the journal of the German Chamber of Medical Doctors since 2009
• Member of the International Board of “Psychiatrie & Psychotherapie,” the journal of the Austrian Society of Psychiatry and Psychotherapy since 2006
• Member of the Advisory Board of “Der Nervenarzt”, the journal of the German Society of Psychiatry, Psychotherapy and Neurology since 2003
• Member of the Advisory Board of “Sucht” [Addiction], the journal of the German Association against Addictive Disorders (DHS) since 2001
• Member of the Advisory Board of “European Psychiatry,” the journal of the Association of European Psychiatrists (AEP) since 2000
• Member of the Advisory Board of “Journal of Studies on Alcoholism” since 2000

PROFESSIONAL ORGANISATIONS:

• Member of the Scientific Advisory Board of the Leibnitz-Institutes for Neurobiology (IfN) Magdeburg since 2010
• Speaker of the German Conference of Chairs of Psychiatric University Departments since 2008
• Member of the Association of European Psychiatrists (AEP) since 2000
• Member of the Society for Nuclear Medicine since 1999
• Member of the German Association for Neuropsychopharmakology and Pharmacopsychiatry (AGNP) since 1999
• Member of the Berlin Society for Philosophy and the Science of Psychiatry. Organizer of the Seminar “Schizophrenia and language” since 1994
• Member of the Society for Neuroscience since 1995·
• Member of the German Society for Clinical Neurophysiology since 1994
• Member of the German Medical Association (Deutsche Ärztekammer), since 1/1988
• Member of the German Society for Hypnosis (DGH), since 1989

RESEARCH FUNDING:

a) Principal Investigator

• Bernstein Focus Grant for Computational Neuroscience Berlin/Hamburg: “Using Computational Models to Understand Mechanisms Underlying Complex Human Learning and its Genetic Basis Across the Life-Span” funded by the Federal Ministry of Education and Research (01GQ0411) co-PI with Prof. Obermayer (TU Berlin), Prof. Lindenberger (Max Planck Institute for Human Development, Berlin), Prof. Gallinat (Charité Berlin), Prof. Büchel (Neuroimage Nord) (01/07/2009-30/06/2014)
• “Orientation of the mental health care system towards the needs of people with a migration background;“ gefördert von der Volkswagen Stiftung; co-PI mit Prof. Dr. Dr. Uwe Koch-Gromus, Universitätsklinikum Hamburg-Eppendorf und Prof. Esat Oðuz Göktepe & Kaan Kora, MD, Department of Psychiatry, Marmara University, School of Medicine, Department of Psychiatry, Istanbul (Turkey) (11/2009-31/10/2012)
• Graduate School “Sensory Computation in Neural Systems” (GRK 1589/1) supported by the German Research Foundation (DFG) (01/01/2010 – 30/06/2014)
• NEUROCURE – Towards a better outcome of neurological disorders (Research cluster as part of the “Exzellenzinitiative des Bundes und der Länder” (38 principal investigators in total)) funded by the German Research Foundation (DFG) (01/11/2007-31/10/2012)
• IMAGEN Genomic Imaging (Genetic and imaging study in adolescents): “Reinforcement-related behaviour in normalbrain function and psychopathology” funded by the European Union (IMAGEN), PI for study site Berlin Andreas Heinz (PI all places: Gunter Schumann, London (037286)) (02/2006 – 02/2011)
• Berlin School of Mind and Brain (Graduate School as part of the “Exzellenzinitiative des Bundes und der Länder” (60 principal investigators in total) (11/0 /2006-10/31/2011)
• “Dopaminergic mechanisms of cue-induced alcohol craving“ funded by the Deutsche Forschungsgemeinschaft (He 2597/4-1, 4-2 & 4-3) (since 4/2000)
• “Serotonin transporter in alcoholism, major depression and obsessive-compulsive disorder“ funded by the Deutsche Forschungsgemeinschaft (He 2597/7-1 & 7/2 & Ba 1026/6-1) (since 12/2001)
• Suizidprävention bei Berliner Frauen mit türkische Migrationshintergrund; DLR/ Federal Ministry of Education and Research Co-PI with Prof. U. Koch (2008-2010)
• “Secondary prevention of schizophrenia. A randomized controlled trial“ funded by the Deutsche Forschungsgemeinschaft & the Federal Ministry of Education and Research (PREVENT) PI for study site Berlin Andreas Heinz, (07/2007.07/2010); co-PIs: Andreas Bechdolf (Köln), Wolfgang Maier (Bonn), Michael Wagner (Bonn),· Wolfgang Gaebel (Düsseldorf), Hans-Jürgen Möller (München), Peter Falkei (Göttingen), Frank Schneider (Aachen) Project with 7 study sites, (KL 970/7-1) plus fundings from Bristol-Myers Squibb
• NGFN plus (01 GS 08 159) (Genetic and imaging study in alcohol-dependent and in schizophrenic patients); NGFN moods (01 GS 08 148), Federal Ministry for Education and Research (06/2008-06/2011)
• PROMO (Mental health for disadvantaged populations), European Union, (01/09/2007-31/08/2010)
• EUGATE (European Migrant Health Care), European Union (01/02/2008-31/01/2011)
• Bernstein Center for Computational Neuroscience Berlin: “Stimulus, genotype and neurotransmitter effects on multimodal brain activation: from hierarchical neuronal systems to systemic disorders” funded by the Federal Ministry of Education and Research (01GQ0411) co-PI with Dr. K. Obermayer (Dept. Mathematics, Fakultaet IV, EE & CS, TU Berlin) (01/09/2004-31/08/2009)
• “Multimodal imaging of dopamine-glutamate interaction during reward processing in schizophrenics and healthy controls“ funded by the Federal Ministry of Education and Research (since 10/2005)
• “Naltrexone-Study (IIIb)”, (EudraCT Nr.2006-006886-18) (since 2007)
• “SWITCH – Early switching strategy for non-response to antipsychotics in schizo-phrenia” (EudraCTNr 2009-012031-1), funded by Federal Ministry of Education and Research (since 06/2009)
• “NeSSy -The Neuroleptic Strategy Study” (EudraCT Nr 2009-010966-47), funded by Federal Ministry of Education and Research (since 01/2010)
• “An open-label study of intramuscular olanzapine depot in patients with schizophrenia or schizoaffective disorder. Clinical phase IIIb” funded by Fa. Lilly Germany GmbH(08/2004-04/2009)
• “A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia” (Clinical Phase IIa-Study in Cooperation with CRO Clinical Research Organisation of Charité Universitätsmedizin) funded by Fa. Johnson & Johnson Pharmaceutical Research & Development (06/2008-12/2008)
• “Efficacy and safety of quetiapine in treating affective symptoms of patients with first episode psychosis – a pilot study, clinical phase IV” funded by IFS Göttingen and Astra Zeneca co-PI with Prof P. Falkei (2007-2009)
• “An open-label prospective trial to evaluate the tolerability, safety and mainatned efficacy of a transition to paliperidone ER in subjects with schizophrenia previously unsuccessfully treated with other oral antipsychotics” (PERFLEX-Study) funded by Fa. Janssen-Cilag GmbH (2007-2008)
• “Postakute Behandlung schizophrener Patienten mit Risperdal-Consta in Ambulanzen, die psychiatrischen Krankenhäusern angeschlossen sind. Prospektive einarmige Studie der klinischen Phase IV“ (RIS-SCH-4091-Study) funded by Fa. Janssen-Cilag GmbH (2007-2008)
• “Effects of a computer-based treatment monitoring tool „CATS“ on the management of mental and physical health in patients recieving atypical antipsychotics.” (CATS-Study (Clinical Analysis of Therapy of Schizophrenia)) funded by Fa. Pfizer Germany (2008-2011)
• “A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Sub-jects With Predominant, Per-sistent Negative Symptoms of Schizophrenia” (EudraCT Nr 2005-002169-35), LKP, (2005-2007)
• “European prediction of psychosis study” funded by the European Union, co-PI with Dr. G. Juckel (grant number QLG4-CT-2001-01081) (2003-2005)
• “Genetics of alcoholism“ funded by the Federal Ministry of Education and Research (NGFN-1 & 2) co-PI with Dr. R. Spanagel· (FKZ:01GS0117) (9/2001-9/2006)
• “Individually adapted therapy of alcoholism“ funded by the Federal Ministry of Education and Research and the State of Baden-Württemberg (FKZ: 01EB0110) co-PI with Prof. K. Mann (12/2001-12/2006
• “Reward system dysfunction in schizophrenia,” “Psychoeducation” and “Early recognition of psychosis” funded by unrestricted grants from Janssen-Cilag and Lilly (since 2002)
• “Monoaminergic dysfunction in alcoholism and schizophrenia“, special volunteer at the National Institute of Mental Health and the National Institute of Alcohol Abuse and Addiction, NIH, Bethesda, funded by the Deutsche Forschungsgemeinschaft (He 2597/1-1) plus travel award (He 2597/5-1) (1995-1997)

b) Co-investigator

• “Functional changes of the reward system in nicotine withdrawal“ funded by the Deutsche Forschungsgemeinschaft (Sm 80/1-1&1-2) (start 4/2004)
• “Pathogenesis and reversibility of alcohol-associated brain atrophy“ funded by the Deutsche Forschungsgemeinschaft (Ma 2013/1-1) (2001-2003)
• “Psychiatry as Science“, summer school for psychiatrists from Eastern Europe, funded by the Volkswagen Stiftung (Helmchen, Sartorius & Heinz) (2001 and 2002)
• “Alcohol-associated diseases“ funded by the State of Baden-Württemberg (2001-2002)
• “Immunological mechanisms in alcohol-associated brain atrophy“ funded by the Research Fund of the medical faculty of the University Clinic Mannheim, Universität Heidelberg (1999-2002)
• “Opioid receptor availability as predictor of therapy outcome in alcoholics – a carfentanil PET study“ funded by the State of Baden-Württemberg (1999-2002)

STATE SERVICE:

Civil service (equivalent to military service)
drafted 1.9.1988 – 28.2.1990,
Neurological University Clinic, St. Josef’s Hospital, Bochum.

COMMUNITY SERVICES:

• Member of Amnesty International (since 2001)
• Counseling of refugees for the “Society for Threatened People” (GfbV), Section Bochum, 1988-1991.
• Organizational and administrative work for the “Society for Threatened People”, Section Berlin, 1985-1988.
• Social work with immigrant children for the Bochum “Initiative for Foreign Children” (IFAK), 1982-1984
• Organizational and administrative work for the Ludwigsburg Club for “Fair Trade with the Third World” 1976-1980

Scholary Interest:

The Department of Psychiatry & Psychotherapy, Charité CCM Berlin, focuses on the neurobiological and psychosocial correlates of mental disorders and on the anthropological construction of disease models. One example is the interaction between social stress factors such as isolation stress with individual genotype on serotonergic dysfunction and substance abuse in non-human primates and in humans (e.g. Heinz et al., 1998; Hinckers et al., 2007). We examined genotype effects on limbic processing of affective stimuli in healthy volunteers and patients suffering from major depression (Heinz et al., 2005; Friedel et al., 2009) and we discussed the disease models and their underlying anthropological assumptions in affective and aggression research (Heinz et al, 2001; Heinz, 2002). Specifically, social assumptions with respect to hierarchical interactions often underlie neurobiological paradigms, which are then limited in their explanatory power for complex neuronal network interactions as e.g. discussed in schizophrenia research, and we described more comprehensive models that include flexible learning alterations in psychiatric disorders (Heinz et al., 2010).

Literature:

• Friedel E, Schlagenhauf F, Sterzer P, Park SQ, Bermpohl F, Ströhle A, Stoy M, Puls I, Hägele C, Wrase J, Büchel C, Heinz A: 5-HTT genotype effect on prefrontal-amygdala coupling differs between major depression and controls. Psychopharmacology 2009; 205(2):261-71.
• Heinz A, Higley JD, Jones DW, Gorey J, Hommer D, Saunders R, Zajicek K, Suomi SJ, Knable MB, Lesch KP, Weinberger DR, Linnoila M: In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am J Psychiat 1998;155:1023-1028
• Heinz A, Mann K, Weinberger DR, Goldman D: Serotonergic dysfunction, negative mood states, and response to alcohol. Alc Clin Exp Res 2001; 25, 487-495
• Heinz A: Dopaminergic dysfunction in alcoholism and schizophrenia–psychopathological and behavioral correlates. Eur Psychiatry. 2002;17(1):9-16.
• Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, Klein S, Grüsser SM, Flor H, Schumann G, Mann K, Büchel C: Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci. 2005;8(1):20-1.
• Heinz A, Schlagenhauf F: Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull. 2010;36(3):472-85.
• Hinckers AS, Laucht M, Schmidt MH, Mann KF, Schumann G, Schuckit MA, Heinz A: Low Level of Response to Alcohol as Associated with Serotonin Transporter Genotype and High Alcohol Intake in Adolescents. Biol Psychiatry 2006;60:282-287